40 patents
Utility
Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
14 Nov 23
The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.
Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
Filed: 20 Oct 22
Utility
Bromodomain inhibitors for androgen receptor-driven cancers
31 Oct 23
Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed.
Sylvie Guichard, Maureen Caligiuri, Anna Ericsson, Qunli Xu, Hesham Mohamed
Filed: 23 Sep 21
Utility
Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
24 Oct 23
The present disclosure is directed to solid and salt forms of inhibitors of the CBP/p300 family of bromodomains made up of salts and crystalline forms of Formula (I).
George Luke, Suresh Babu
Filed: 23 Sep 21
Utility
Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
17 Oct 23
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains.
Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
Filed: 10 Feb 22
Utility
Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
15 Aug 23
The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
George P. Luke, Pratik Sheth
Filed: 24 Feb 21
Utility
Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
16 May 23
The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds.
Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
Filed: 23 Apr 21
Utility
Composite conduit formwork structure and method of fabrication
28 Feb 23
The disclosure presents a composite conduit formwork structure which includes a cylindrical outer casing adapted to bond with a cylindrical inner casing which are maintained at a fixed distance apart by a plurality of radial stanchions.
Scott Armstrong
Filed: 10 Nov 20
Utility
Inhibiting mutant IDH-1
14 Feb 23
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 16 May 19
Utility
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
31 Jan 23
This disclosure relates to compositions and methods for inhibiting mutant IDH1, useful in treatment of mIDH1 cancers including AML, as well as mIDH1-positive solid tumors such as glioma.
Jian Lin, George P. Luke, Madhu Mondal
Filed: 19 Nov 20
Utility
Reconfigurable composite floor formwork and method of use
3 Jan 23
The disclosure presents a reconfigurable composite floor formwork which defined by a plurality of interlocking fiberglass panels formed into profiles which may be moved and adapted to provide a concrete form for a floor or ceiling.
Scott Armstrong
Filed: 10 Nov 20
Utility
Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
27 Dec 22
Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
Filed: 4 Oct 19
Utility
Composite subgrade formwork and method of use
13 Dec 22
The disclosure presents a formwork system which utilizes Fiber Reinforced Polymer (FRP) panels to create modular segments to form and reinforce concrete subgrade structures.
Scott Armstrong
Filed: 10 Nov 20
Utility
Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
15 Nov 22
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 4 Dec 20
Utility
Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
15 Nov 22
Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
Filed: 23 Nov 20
Utility
Compositions for activating pyruvate kinase
26 Jul 22
Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).
Xiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, Jr., Lorna Mitchell, Tatiana Shelekhin
Filed: 2 Oct 20
Utility
Inhibiting mutant IDH-1
5 Jul 22
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 25 Nov 19
Utility
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
26 Apr 22
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Patrick F. Kelly, Susan Ashwell, Blythe Thomson, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
Filed: 4 Jun 20
Utility
Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
5 Apr 22
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains.
Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
Filed: 14 Sep 18
Utility
Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone
8 Mar 22
George P. Luke, Stephen Hubbs, Matthew W. Martin, Shawn E. R. Schiller, Robert Wenslow, Yawei Shi, Jun Huang
Filed: 28 Aug 20
Utility
Inhibiting CREB binding protein (CBP)
22 Feb 22
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains.
Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela West, Jennifer R. Downing, Anna Ericsson
Filed: 8 Jun 20